Loading...
GNS logo

Genus plcLSE:GNS Aktienübersicht

Marktkapitalisierung UK£1.6b
Aktienkurs
UK£23.56
UK£31.63
25.5% unterbewertet intrinsischer Abschlag
1Y17.5%
7D-2.2%
Wert des Portfolios
​
Siehe

Genus plc

LSE:GNS Lagerbericht

Marktkapitalisierung: UK£1.6b

Genus (GNS) Aktienübersicht

Genus plc produziert und verkauft Tiergenetik an Landwirte in Nordamerika, Lateinamerika, dem Vereinigten Königreich, dem übrigen Europa, dem Nahen Osten, Russland, Afrika und Asien. Mehr Details

GNS grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung1/6
Künftiges Wachstum0/6
Vergangene Leistung1/6
Finanzielle Gesundheit5/6
Dividenden0/6

Belohnungen

In diesem Jahr profitabel geworden

Analysten sind sich einig, dass der Aktienkurs um 34.1%

Risikoanalyse

Die Erträge werden in den nächsten 3 Jahren voraussichtlich um durchschnittlich 1.1% pro Jahr sinken.

Große einmalige Posten, die sich auf die Finanzergebnisse auswirken


GNS Community Fair Values

Create Narrative

See what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives
GANX logo
GANXFeatured

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
View narrative
Community Contributor
US$7.6FV • 75.3% unterbewertet intrinsischer Abschlag
5022.2%Revenue growth p.a.
3.7k
23
2
54
29d ago

Genus plc Wettbewerber

Preisentwicklung & Leistung

Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Genus
Historische Aktienkurse
Aktueller AktienkursUK£23.56
52-Wochen-HochUK£32.29
52-Wochen-TiefUK£18.90
Beta0.94
1 Monat Veränderung-3.84%
3 Monate Veränderung-25.44%
1 Jahr Veränderung17.51%
3 Jahre Veränderung-15.07%
5 Jahre Veränderung-53.39%
Veränderung seit IPO1,645.19%

Aktuelle Nachrichten und Updates

GNS: Gene Editing Breakthrough And China JV Will Drive Medium Term Upside

Analysts have lifted their fair value estimate for Genus from £35.00 to £37.00, citing updated assumptions on discount rates, growth, margins, and future P/E multiples reflected in recent Street research, including the £1.00 price target increase reported by Berenberg. Analyst Commentary Recent Street research on Genus points to a more constructive tone on the shares, with bullish analysts reflecting this in higher price targets and refreshed valuation work.

GNS: Gene Editing Progress And China JV Execution Will Shape Medium-Term Upside

Analysts have raised their price target for Genus by £1.00, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E as the key drivers behind the change. Analyst Commentary Bearish analysts view the higher price target and updated assumptions as leaving limited room for error.

GNS: China JV And Gene Editing Progress Will Drive Medium Term Upside

Analysts have nudged their price target on Genus up by £1.00, citing updated fair value and discount rate assumptions along with revised expectations for revenue growth, profit margins and future P/E as the key drivers for the change. Analyst Commentary Bullish Takeaways Bullish analysts see the £1.00 uplift in the price target as aligned with updated fair value work, suggesting that their revised assumptions on revenue growth and margins still support the current valuation framework.

GNS: China JV And Gene Editing Progress Will Support Medium Term Upside

Analysts have raised their price target on Genus by £1.00, supported by updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E multiples. Analyst Commentary Analysts lifting their fair value assumptions for Genus are signalling a shift in how they view the balance between the company’s growth potential and execution risks.

Recent updates

GNS: Gene Editing Breakthrough And China JV Will Drive Medium Term Upside

Analysts have lifted their fair value estimate for Genus from £35.00 to £37.00, citing updated assumptions on discount rates, growth, margins, and future P/E multiples reflected in recent Street research, including the £1.00 price target increase reported by Berenberg. Analyst Commentary Recent Street research on Genus points to a more constructive tone on the shares, with bullish analysts reflecting this in higher price targets and refreshed valuation work.

GNS: Gene Editing Progress And China JV Execution Will Shape Medium-Term Upside

Analysts have raised their price target for Genus by £1.00, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E as the key drivers behind the change. Analyst Commentary Bearish analysts view the higher price target and updated assumptions as leaving limited room for error.

GNS: China JV And Gene Editing Progress Will Drive Medium Term Upside

Analysts have nudged their price target on Genus up by £1.00, citing updated fair value and discount rate assumptions along with revised expectations for revenue growth, profit margins and future P/E as the key drivers for the change. Analyst Commentary Bullish Takeaways Bullish analysts see the £1.00 uplift in the price target as aligned with updated fair value work, suggesting that their revised assumptions on revenue growth and margins still support the current valuation framework.

GNS: China JV And Gene Editing Progress Will Support Medium Term Upside

Analysts have raised their price target on Genus by £1.00, supported by updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E multiples. Analyst Commentary Analysts lifting their fair value assumptions for Genus are signalling a shift in how they view the balance between the company’s growth potential and execution risks.

GNS: Gene Editing Execution And Regulatory Timelines Will Constrain Medium-Term Upside

Analysts have raised their fair value estimate for Genus from £24.00 to £25.50, reflecting updated assumptions on revenue growth, profit margins and the potential of its gene editing technology as highlighted in recent research. Analyst Commentary Recent street research on Genus highlights a mix of optimism around its gene editing platform and caution around how that potential is reflected in the share price.

GNS: Gene Editing Progress And China JV Will Shape Balanced Medium Term Outlook

Genus's updated analyst price target reflects a modest uplift in estimated fair value to £30.82, supported by higher assumed revenue growth and a richer future P/E multiple, even as analysts factor in a slightly higher discount rate and softer profit margins. Analyst Commentary Recent Street research on Genus points to a generally constructive stance, with analysts revisiting their models and price targets as they reassess the company’s growth potential and execution risks.

GNS: Gene Editing Breakthrough Will Drive Medium Term Upside Potential

Narrative Update on Genus Analysts have lifted their price target on Genus to £31.00 from £29.00, citing the company's gene editing technology and its perceived medium term upside potential as key reasons for the change. Analyst Commentary Bullish analysts are highlighting Genus as a name with medium term upside potential, underpinned by its gene editing capabilities and recent supportive price target work.

GNS: Gene Editing Potential Will Drive Balanced Medium-Term Opportunity And Execution Risk

Narrative Update Analysts now see Genus as fairly valued in a range of £30.50 to £31.00. This reflects a modestly revised P/E assumption, slightly higher revenue growth and profit margin expectations, and a growing focus on the potential of its gene editing technology for medium term upside.

Calculating The Fair Value Of Genus plc (LON:GNS)

Jan 06
Calculating The Fair Value Of Genus plc (LON:GNS)

GNS: Gene Editing Platform Will Shape Balanced Medium-Term Upside And Execution Risks

Genus's analyst price target has been raised from about £18.80 to £24.00 per share as analysts highlight the upside from its gene editing platform and reaffirm Buy ratings alongside recent target hikes from major banks. Analyst Commentary Recent research updates underscore a constructive stance on Genus, with buy ratings supported by the view that its gene editing platform could materially expand medium term earnings power.

GNS: Gene Editing Platform Will Drive Medium Term Upside Despite Execution Risks

Analysts have nudged their price target on Genus higher to £31.00 from £29.00, citing increasing confidence in the medium term upside from its gene editing platform and a modest uplift in expected profitability, even as growth assumptions normalize slightly. Analyst Commentary Bullish analysts highlight that the uplift in price targets reflects growing conviction that Genus can translate its gene editing capabilities into sustained, above-market earnings growth over the medium term.

GNS: Future China Joint Venture Will Improve Near-Term Shareholder Returns

Analysts have increased their price target for Genus from £29.00 to £31.00. This reflects greater confidence in the company's outlook despite moderating growth forecasts and a slightly higher discount rate.

Benign Growth For Genus plc (LON:GNS) Underpins Its Share Price

Nov 15
Benign Growth For Genus plc (LON:GNS) Underpins Its Share Price

Genus (LON:GNS) Is Paying Out A Dividend Of £0.217

Oct 28
Genus (LON:GNS) Is Paying Out A Dividend Of £0.217

We Like Genus' (LON:GNS) Earnings For More Than Just Statutory Profit

Oct 18
We Like Genus' (LON:GNS) Earnings For More Than Just Statutory Profit

Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217

Oct 11
Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217

FDA Approval Of PRP Program In 2025 Will Open Significant Revenue Stream

The upward revision in Genus’s price target reflects improved analyst expectations, driven by notable increases in both forecast revenue growth (from 4.0% to 4.9% per annum) and net profit margin (from 7.88% to 8.73%), resulting in a new fair value of £27.97. What's in the News Genus and Beijing Capital Agribusiness Co. (BCA) have accelerated the formation of a Chinese joint venture to commercialise PRRS 2 Resistant Pig (PRP), with BCA holding 51% and Genus 49%.

Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217

Sep 07
Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217

There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise

Jul 25
There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise

Estimating The Fair Value Of Genus plc (LON:GNS)

Jul 22
Estimating The Fair Value Of Genus plc (LON:GNS)

Genus plc (LON:GNS) Stock Catapults 36% Though Its Price And Business Still Lag The Industry

May 10
Genus plc (LON:GNS) Stock Catapults 36% Though Its Price And Business Still Lag The Industry

An Intrinsic Calculation For Genus plc (LON:GNS) Suggests It's 21% Undervalued

Apr 18
An Intrinsic Calculation For Genus plc (LON:GNS) Suggests It's 21% Undervalued
User avatar

Regulatory Approvals And Sustainability Initiatives Will Strengthen Future Market Position

Expansion in the porcine business and PRRS resistant pig commercialization boosts revenue stability and growth through innovation and market penetration.

There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise

Feb 01
There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise

Lacklustre Performance Is Driving Genus plc's (LON:GNS) Low P/S

Nov 20
Lacklustre Performance Is Driving Genus plc's (LON:GNS) Low P/S

Genus (LON:GNS) Has Affirmed Its Dividend Of £0.217

Oct 23
Genus (LON:GNS) Has Affirmed Its Dividend Of £0.217

There May Be Some Bright Spots In Genus' (LON:GNS) Earnings

Oct 22
There May Be Some Bright Spots In Genus' (LON:GNS) Earnings

Genus plc Just Missed EPS By 72%: Here's What Analysts Think Will Happen Next

Sep 08
Genus plc Just Missed EPS By 72%: Here's What Analysts Think Will Happen Next

The Price Is Right For Genus plc (LON:GNS)

Jun 16
The Price Is Right For Genus plc (LON:GNS)

Estimating The Fair Value Of Genus plc (LON:GNS)

Apr 20
Estimating The Fair Value Of Genus plc (LON:GNS)

Is Genus (LON:GNS) Using Too Much Debt?

Mar 25
Is Genus (LON:GNS) Using Too Much Debt?

With A 26% Price Drop For Genus plc (LON:GNS) You'll Still Get What You Pay For

Mar 05
With A 26% Price Drop For Genus plc (LON:GNS) You'll Still Get What You Pay For

Genus (LON:GNS) Has Affirmed Its Dividend Of £0.103

Feb 25
Genus (LON:GNS) Has Affirmed Its Dividend Of £0.103

Getting In Cheap On Genus plc (LON:GNS) Might Be Difficult

Jan 17
Getting In Cheap On Genus plc (LON:GNS) Might Be Difficult

Does This Valuation Of Genus plc (LON:GNS) Imply Investors Are Overpaying?

Dec 10
Does This Valuation Of Genus plc (LON:GNS) Imply Investors Are Overpaying?

We Think Genus (LON:GNS) Is Taking Some Risk With Its Debt

Nov 03
We Think Genus (LON:GNS) Is Taking Some Risk With Its Debt

Aktionärsrenditen

GNSGB BiotechsGB Markt
7D-2.2%-0.8%-0.2%
1Y17.5%16.7%19.7%

Rendite im Vergleich zur Industrie: GNS übertraf die Branche UK Biotechs , die im vergangenen Jahr eine Rendite von 16.7 erzielte.

Rendite vs. Markt: GNS hinter dem Markt UK zurück, der im vergangenen Jahr eine Rendite von 19.7 erzielte.

Preisvolatilität

Is GNS's price volatile compared to industry and market?
GNS volatility
GNS Average Weekly Movement5.7%
Biotechs Industry Average Movement9.9%
Market Average Movement5.6%
10% most volatile stocks in GB Market11.5%
10% least volatile stocks in GB Market3.2%

Stabiler Aktienkurs: GNS hatte in den letzten 3 Monaten im Vergleich zum UK -Markt keine signifikante Preisvolatilität.

Volatilität im Zeitverlauf: GNSDie wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

GegründetMitarbeiterCEOWebsite
19943,190JK Kokkewww.genusplc.com

Genus plc produziert und verkauft Tiergenetik an Landwirte in Nordamerika, Lateinamerika, dem Vereinigten Königreich, dem übrigen Europa, dem Nahen Osten, Russland, Afrika und Asien. Das Unternehmen ist in drei Segmenten tätig: Genus PIC, Genus ABS und Genus Forschung und Entwicklung. Unter den Marken Genus und Bovec bietet es Samen und Embryonen für Milch- und Rinderbullen an, unter der Marke PIC Zuchtschweine und Samen sowie technische Dienstleistungen und Beratung.

Genus plc's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Genus im Vergleich zum Marktanteil des Unternehmens?
GNS grundlegende Statistiken
MarktanteilUK£1.58b
Gewinn(TTM)UK£47.50m
Umsatz(TTM)UK£672.00m
33.2x
Kurs-Gewinn-Verhältnis
2.3x
Kurs-Umsatz-Verhältnis

Ist GNS zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
GNS Gewinn- und Verlustrechnung (TTM)
EinnahmenUK£672.00m
Kosten der EinnahmenUK£402.40m
BruttogewinnUK£269.60m
Sonstige AusgabenUK£222.10m
GewinnUK£47.50m

Zuletzt gemeldete Gewinne

Dec 31, 2025

Datum des nächsten Gewinnberichts

Sep 10, 2026

Gewinn per Aktie (EPS)0.71
Bruttomarge40.12%
Nettogewinnspanne7.07%
Schulden/Eigenkapital-Verhältnis46.4%

Wie hat sich GNS auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

1.4%
Aktuelle Dividendenrendite
46%
Ausschüttungsquote

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/01 10:28
Aktienkurs zum Tagesende2026/05/01 00:00
Gewinne2025/12/31
Jährliche Einnahmen2025/06/30

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Genus plc wird von 17 Analysten beobachtet. 12 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Robert ChantryBerenberg
Matthew LloydBNP Paribas
Alexander JonesBofA Global Research